US ‘eroding’ lead in rare diseases a matter of national security: Report - BioSpace
• A Congressional advisory panel has warned that the U.S. is losing its lead in rare disease drug development, labeling the trend a matter of national security. • To combat this, the panel recommends implementing supportive policies, including a finalized FDA platform designation and the adoption of novel trial designs for small patient populations. • The FDA is already taking action via a new pilot program to shorten the timeline from drug identification to first-in-human studies and improve submission quality.
biospace.com



![[MUST WATCH] NASA-Raumsonde Psyche macht aus Mars-Vorbeiflug eine beeindruckende Tour zum Roten Planeten](/_next/image?url=https%3A%2F%2Fcdn.zmescience.com%2Fwp-content%2Fuploads%2F2026%2F07%2FE2_PIA26749_Psyche_Imager_Mars_Mosaic1_F247E.width-1320.jpg&w=1920&q=85)
